Gabapentin
Product Images NDC 52125-816

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 52125-816). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Mm1)

Chemical structure of Gabapentin, showing a cyclohexane ring attached to a methylene amine group (CH2NH2) and a methylene carboxylic acid group (CH2CO2H).*

FDA Label Image

Mm2 (Mm2)

A line graph displaying weekly mean pain scores over an 8-week period for placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks from baseline through week 8, and the y-axis shows mean pain scores ranging from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Mm3 (Mm3)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2,' showing mean pain scores over a 7-week period. The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain scores from 0 to 10. Three lines compare placebo and Gabapentin at 1800 mg/day and 2400 mg/day during a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Mm4 (Mm4)

A bar graph showing the percentage of responders with at least 50% reduction in pain score at endpoint in controlled PHN studies. The graph compares placebo (PBO) versus different doses of gabapentin (GBP) across two studies. Study 1 shows 12% responders for placebo and 29% for gabapentin 3600 mg. Study 2 shows 14% responders for placebo, 32% for gabapentin 1800 mg, and 34% for gabapentin 2400 mg. Statistical significance is indicated for certain comparisons.*

FDA Label Image

Mm5 (Mm5)

A scatter plot chart showing the responder rate difference from placebo (%) versus daily dose (mg) for gabapentin in adjunctive therapy studies in patients aged 12 and older. The chart compares results from three studies labeled as STUDY a, STUDY b, and STUDY c, each represented with different colored markers, illustrating the dose-response relationship.*

FDA Label Image

Mm6 (Mm6)

Gabapentin 600 mg tablet packaging label from Remedyrepack Inc. The label includes NDC codes and packaging details, indicating a quantity of 30 oblong tablets. It also displays an expiration date of January 2016 and references the manufacturer and distributor information.*

FDA Label Image

Mm7 (Mm7)

Gabapentin blister card packaging by REMEDYREPACK INC. The card contains 26 capsules arranged in a 4-column grid with a blue and white color scheme. The top right corner displays the Diamond Pharmacy Services logo. The left side has a blue 'START' label indicating the beginning of the dosage sequence.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.